Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Ongoing Initiated Aug 8, 2026 (2 months ago)

Menow Sunscreen Pressed Powder Spf35 PA+++

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

cGMP Deviations

Cause type: cGMP deviation

Departures from current Good Manufacturing Practice found in production or during FDA inspection. A broad quality-system cause: the batch was made under conditions that fall short of FDA manufacturing standards. All cgmp deviation recalls.

What was recalled

MENOW SUNSCREEN PRESSED POWDER SPF35 PA+++, Net content, 9g/0.32 oz, Manufactured by: Shantzu Qiwei Industry Co. Ltd, Add: Quiwei Building, Yingloinguan, Xiashan, Chaonan district, Shantou City, Guangdong Province, China

Recalling firm
SHANTOU Qiwei industrial Co., Ltd
Origin
China
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0854-2026 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall.

Other cgmp deviation recalls from 2026

All cgmp deviation recalls
Class II · Moderate risk

Carbamazepine Tablets

CGMP deviations: tablets with black specks.

Ongoing cGMP deviation Golden State Medical Supply Inc. NDC 51407-215-10 D-0771-2026
Class II · Moderate risk

Daptomycin

CGMP Deviations

Ongoing cGMP deviation Baxter Healthcare Corporation NDC 0338-0718-12 D-0821-2026